Travere Therapeutic (TVTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TVTX Travere Therapeutic

Watchlist

5.260
-0.130-2.41%

Close Apr 26 16:00 ET

5.380
+0.120+2.28%

Post 16:30 ET

400.33MMarket Cap-3506P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 24 14:48 ET
Express News | HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19
Moomoo 24/7Apr 24 14:38 ET
Travere, CSL Win Conditional Nod for Kidney Disease Therapy in EU
Seeking AlphaApr 24 08:31 ET
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephro
MT NewswiresApr 24 04:27 ET
Express News | Travere Therapeutics Inc - CSL Vifor Expects to Launch Filspari in First European Markets in Second Half of 2024.
Moomoo 24/7Apr 24 03:00 ET
Express News | CSL Vifor and Travere Therapeutics Announce European Commission Approves Filspari® (Sparsentan) for the Treatment of Iga Nephropathy
Moomoo 24/7Apr 24 03:00 ET

Comments

Trytosaveabit

Apr 24 17:27

Update

$Travere Therapeutic(TVTX.US)$ Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...

Meltyy

Apr 18 16:34

🎯 Ph 3 readouts in Q2 2024...

$Travere Therapeutic(TVTX.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...

Moomoo AI

Mar 15 22:07

The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.

Further Weakness as Travere Therapeutics (NASDAQ:TVTX) Drops 14% This Week, Taking Three-year Losses to 72%

Trytosaveabit

Feb 23 20:11

Update

$Travere Therapeutic(TVTX.US)$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024

Moomoo AI

Jan 9 19:48

Travere Therapeutics' future revenue performance is expected to decline, contributing to its low P/S. Shareholders accept this as they anticipate no pleasant surprises in future revenue. A strong share price rise seems unlikely under these circumstances.